logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Epizyme, Inc.


USPTO Granted Patents = 159

% Expired Patents = 11.3



Trademarks = 7

Forward Citations = 2,314

Loading Chart...
Loading Chart...

69 inventors (with patents filed for the assignee):

goldMedal Richard Chesworth (85 out of 107 patents)

silverMedal Kevin Wayne Kuntz (73 out of 85 patents)

bronzeMedal Kenneth William Duncan (46 out of 50 patents)

4.  Lorna Helen Mitchell (33 out of 33 patents)

5.  Gideon Shapiro (33 out of 75 patents)

6.  Heike Keilhack (32 out of 32 patents)

7.  Sarah Kathleen Knutson (31 out of 31 patents)

8.  Lei Jin (27 out of 29 patents)

9.  Michael John Munchhof (26 out of 53 patents)

10.  Paula Ann Boriack-Sjodin (25 out of 28 patents)

11.  Edward James Olhava (21 out of 45 patents)

12.  Masashi Seki (19 out of 19 patents)

13.  John Emmerson Campbell (18 out of 42 patents)

14.  Oscar Miguel Moradei (17 out of 32 patents)

15.  Christine Klaus (16 out of 16 patents)


Core Competencies:
EZH2 Inhibitors
Arginine Methyltransferase
Combination Therapy
Histone Methyltransferase
Cancer Treatment
Substituted Benzene Compounds
PRMT5 Inhibitors
Substituted Purine Compounds
Isoxazole Carboxamides
CARM1 Inhibitors
Heteroaryl Compounds

159 patents:

1. 12691111 - SETD2 inhibitors and related methods and uses, including combination therapies (2026-07-28),
2. 12251386 - Salt form of a human histone methyltransferase EZH2 inhibitor (2025-03-18),
3. 12168016 - Aryl-OR heteroaryl-substituted benzene compounds (2024-12-17),
4. 12168015 - Aryl-or heteroaryl-substituted benzene compounds (2024-12-17),
5. 12168014 - Method for treating cancer (2024-12-17),
6. 12162865 - Methods of treating cancer (2024-12-10),
7. 12161645 - Aryl-or heteroaryl-substituted benzene compounds (2024-12-10),
8. 12116358 - Substituted indoles and methods of use thereof (2024-10-15),
9. 11952572 - Methods of treating cancer by inhibiting SETD2 (2024-04-09),
10. 11951109 - EZH2 inhibitors for treating lymphoma (2024-04-09),
11. 11951108 - Combination therapy for treating cancer (2024-04-09),
12. 11834455 - Carm1 inhibitors and uses thereof (2023-12-05),
13. 11786533 - Use of EZH2 inhibitors for treating cancer (2023-10-17),
14. 11753433 - Methods of synthesizing substituted purine compounds (2023-09-12),
15. 11685732 - MYST family histone acetyltransferase inhibitors (2023-06-27),
Company Overview
Epizyme, Inc. is a biotechnology company based in Cambridge, MA, specializing in innovative cancer treatments. The company focuses on developing therapies that target specific genetic and epigenetic drivers of cancer, particularly through the use of EZH2 inhibitors and arginine methyltransferase inhibitors. Their research encompasses combination therapies and the exploration of histone methyltransferases, aiming to provide effective solutions for patients with various malignancies. Epizyme is committed to advancing precision medicine in oncology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Epizyme, Inc. USPTO Patent Assignee Logo
159 Patents

#17 in Cambridge, MA

#134 in Massachusetts

#2,500 in US

#5,182 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Epizyme, Inc.

Forward Citations = 2,314

69 inventors:

goldMedal Richard Chesworth (85 out of 107 patents)

silverMedal Kevin Wayne Kuntz (73 out of 85 patents)

bronzeMedal Kenneth William Duncan (46 out of 50 patents)

4.  Lorna Helen Mitchell (33 out of 33 patents)

5.  Gideon Shapiro (33 out of 75 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Epizyme, Inc.. Retrieved from https://idiyas.com/company/epizyme

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…